CETP

Catalog No.	Product Name	Information	Product Use Citations
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S2772	Dalcetrapib (JTT-705)	Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3.	Atherosclerosis, 2014, 235(2):449-62
S2792	Torcetrapib	Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.	J Immunother Cancer, 2024, 12(11)e009805
S2925	Evacetrapib (LY2484595)	Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S2772	Dalcetrapib (JTT-705)	Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3.	Atherosclerosis, 2014, 235(2):449-62
S2792	Torcetrapib	Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.	J Immunother Cancer, 2024, 12(11)e009805
S2925	Evacetrapib (LY2484595)	Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.

CETP Products

Choose Selective CETP Inhibitors

CETPSignaling Pathway